Division of Medical Oncology, Department of Medicine, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
Section of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Can J Gastroenterol Hepatol. 2018 Feb 12;2018:1863535. doi: 10.1155/2018/1863535. eCollection 2018.
Pancreatic cancer continues to represent one of the leading causes of cancer-related morbidity and mortality in the developed world. Over the past decade, novel systemic therapy combination regimens have contributed to clinically meaningful and statistically significant improvements in overall survival as compared to conventional monotherapy. However, the prognosis for most patients remains guarded secondary to the advanced stages of disease at presentation. There is growing consensus that outcomes can be further optimized with the use of predictive and prognostic biomarkers whereby the former can be enriching for patients who would benefit from therapies and the latter can inform decision-making regarding the need and timing of advanced care planning. One of the challenges of current biomarkers is the lack of standardization across clinical practices such that comparability between jurisdictions can be difficult or even impossible. This inconsistency can impede widespread implementation of their use. In this review article, we provide a comprehensive overview of the contemporary treatment options for pancreatic cancer and we offer some insights into the existing landscape and future directions of biomarker development for this disease.
胰腺癌仍然是发达国家癌症相关发病率和死亡率的主要原因之一。在过去的十年中，与传统的单一疗法相比，新型的系统治疗联合方案在总体生存方面取得了有临床意义和统计学意义的显著改善。然而，由于大多数患者在就诊时疾病已处于晚期，预后仍然不容乐观。越来越多的人认为，可以通过使用预测和预后生物标志物来进一步优化结果，前者可以使那些从治疗中受益的患者受益，后者可以为是否需要和何时进行高级护理规划做出决策。当前生物标志物的挑战之一是缺乏临床实践中的标准化，使得不同司法管辖区之间的可比性变得困难甚至不可能。这种不一致会阻碍它们的广泛应用。在这篇综述文章中，我们全面概述了胰腺癌的当代治疗选择，并对该疾病的现有现状和未来生物标志物发展方向提供了一些见解。
